Drugs / F18CETO
F18CETO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05361083 | Sep 2019 → Apr 2021 | adrenal cortex carcinoma, aldosterone-producing adrenal cortex adenoma, endogenous Cushing syndrome, non-functioning adrenal cortex adenoma | Uppsala University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F18CETO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05361083 ↗ |
| Known as | [18F]CETO | “Therefore, we evaluated para-chloro-2-[18F]fluoroethyl-etomidate, [18F]CETO, a fluorine-18 (T1/2=109.8 min) analogue, as a potential new adrenocortical PET tracer.” PMID 38771379 ↗ May 2024 |
| Known as | para-chloro-2-[18F]fluoroethyl-etomidate | “Therefore, we evaluated para-chloro-2-[18F]fluoroethyl-etomidate, [18F]CETO, a fluorine-18 (T1/2=109.8 min) analogue, as a potential new adrenocortical PET tracer.” PMID 38771379 ↗ May 2024 |
| Modality | Diagnostic / imaging agent | “a PET tracer for adrenocortical imaging” PMID 38771379 ↗ May 2024 |